About NeuroDawn
NeuroDawn is a company based in China founded in 2021. It operates as a B2B. NeuroDawn has raised $10.76 million across 1 funding round from investors including Simcere Pharma, 2Y-Chem and Balancing Capital. NeuroDawn operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.76 M (USD)
in 1 rounds
-
Latest Funding Round
$10.76 M (USD), Series A
Aug 23, 2021
-
Investors
Simcere Pharma
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NeuroDawn
NeuroDawn has successfully raised a total of $10.76M through 1 strategic funding round. The most recent funding activity was a Series A round of $10.76 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeuroDawn
NeuroDawn has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Simcere Pharma, 2Y-Chem and Balancing Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Novel oncology and immunology therapeutics are developed and commercialized.
|
Locked | Locked | Locked | |
|
Specializes as a CDMO for manufacturing API products in the biopharma sector.
|
Locked | Locked | Locked | |
|
Manages a real estate fund with diverse investment strategies for optimal returns.
|
Locked | Locked | Locked |
Investor details for NeuroDawn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeuroDawn
Investment portfolio details for NeuroDawn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeuroDawn
Detailed financials for NeuroDawn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurodawn Comparisons
Peer comparison for NeuroDawn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeuroDawn
NeuroDawn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of NeuroDawn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurodawn
Complete news archive for NeuroDawn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroDawn
NeuroDawn was founded in 2021.
NeuroDawn is headquartered in China.
NeuroDawn is a funded company, having raised a total of $10.76M across 1 funding round to date.
NeuroDawn, established in 2021, excels in providing healthcare solutions, advancing biotech innovations, therapeutics, and cns diseases. Develops innovative therapeutic technologies for central nervous system diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
NeuroDawn's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
NeuroDawn has 3 investors. Key investors include Simcere Pharma, 2Y-Chem, and Balancing Capital.